VIR-7831 for the Early Treatment of COVID-19 in Outpatients

NCT04545060 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1057

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

BIOLOGICAL: VIR-7831 (sotrovimab)
DRUG: Placebo

Sponsor

Vir Biotechnology, Inc.

Collaborators

[object Object]